"nobodymd00", I posted the site twice. For some reason the first post didn't work.

Did you try this one? If it doesn't work I am out of ideas.

http://www.wsw.com/webcast/rrshq20/nnvc/

Weedie,

Try this:

http://www.wsw.com/webcast/rrshq20/nnvc/

Hope this works. You may need to register first.

Weedie, You can still see the slides and hear the audio. I encourage you to do so at your own risk as it's "pom pom" worthy.

Here's the link I used.

http://www.wsw.com/webcast/rrshq20/nnvc.

Wild,

"D3", I like it!

Inability to hear the questions was a shortcoming of the conference a/v people. On a couple of occasions Seymour did repeat the question and then answered.

I also was not able to hear the question you mentioned. I believe it was around viruses that did not have an "envelope?". The person posing the question seemed to be stating his case rather than asking a direct question. I felt that Seymour picked up on this and decided this was neither the time or place.

Better audio coverage of Q&A should be brought to the conference's attention. I'm not sure how or if I can do this. Ideas anyone?

After having offered what I considered to be constructive criticism on Dr. Seymour's earlier presentation(s) I feel compelled to acknowledge what I view as significant improvement.

Seymour seemed to feel more confident and sounded more relaxed. I appreciated how he mentioned the short human trials necessary for Flu-cide and his mention of numerous roll-outs following the initial Flu-cide FDA submission.

I also appreciated the fresh slides.

I've often wondered if the "sounds too good to be true" factor was possibly holding investors back. Seymour addressed the "too good to be true" head on.

Good work Dr. Seymour and thank you.

Now able to access.

Thank you.

DF,

Not sure if it is just me but when I tried the Google doc link I get the following:

Sorry, we are unable to retrieve the document for viewing or you don't have permission to view the document.
Please try again later.

"manny t",

The PZG results exceeded all expectations.

A projected PZG s/p of $15.00 by end of 2011 may prove to be low. $17-$20 easily in the realm of possibility.

Diabetes associated with inflammation. I was not aware of the studies underway regarding the association between inflammation and diabetes.

If Star Scientific is able to produce formal empirical studies demonstrating Anatabloc's (anatabine) ability to reduce inflammation the possibilities seem limitless.

http://www.buffalo.edu/ubreporter/archives/vol34/vol34n5a/articles/DonahueDiabetes.html

Good work! Anxious to hear your report.

Thank you.

I think you may be correct in that Anatabloc may be a ways from replacing many prescription meds but there may be a few.

One that I had in mind was Flomax (Tamsulosin) "Tamsulosin is used in men to treat the symptoms of an enlarged prostate (benign prostatic hyperplasia or BPH) which include difficulty urinating (hesitation, dribbling, weak stream, and incomplete bladder emptying), painful urination, and urinary frequency and urgency".

Flomax retails for apx $30 - $40 per month. The side effects include:

Abnormal ejaculation -- occurring in up to 18.1 percent of people (see Flomax Sexual Side Effects)
Runny or stuffy nose -- in up to 17.9 percent
Dizziness -- in up to 17.1 percent
Infections, including the common cold or flu -- in up to 10.8 percent
General body pain -- in up to 8.5 percent
Back pain -- in up to 8.3 percent
Diarrhea -- in up to 6.2 percent
Sore throat -- in up to 5.8 percent.


There are several less common side effects of Flomax that occurred in 1 to 5 percent of people:


Increased coughing
Sleepiness
Chest pain
Upset stomach (nausea)
Sinus infection (sinusitis)
Decreased sex drive (libido)
Blurred vision
Tooth problems
Trouble sleeping (insomnia)
Spinning sensation (vertigo).

I've also read that many doctors continue to prescribe statins even after cholesterol has been reduced to acceptable levels. The reason being that statins contribute to controlling inflammation.

One medication has side effects. Two medications have compounded side effects. Three....

shank,

I've had the same thoughts about pricing but then realized that the $100 per month is at the six tab a day maximum recommended dosage.

An exploratory dosage of 3 tabs a day reduces monthly cost to $50.

If Anatabloc delivers as advertised a six tab a day regimen at $100 per month may be considered a bargain. Particularly if the price is offset by discontinuing other prescribed or OTC medications.

My biggest concern about Anatabloc's success is counterfeiting. I don't think it will be long before we see similarly named "generic" products with $49.99 (or lower)price points. Unfortunately most counterfeits contain little if any active ingredients and this could give the whole anatabine concept the proverbial black eye.

Of course, there is always the possibility that I'm worrying to much. Anatabloc's success is important to me on multiple levels.

There has been reference to prostrate and Anatabloc



8-13-2010



Dr. John L. Faessel

ON THE MARKET

Commentary and Insights


A Best Idea UPDATE for 2011 & More on the Ultimate Test – On Me...

I’ve Tried It and It Works

Star Scientific Inc. (CIGX) $3.86 Nasdaq

I think the market gave us another ‘freebie’ entry point here.

Yesterday the stock market experienced its sixth straight down day that sliced about 5% off the major indexes; the selloff capped the worst down-leg in a year. Moreover the shares of Star Scientific (CIGX) closed down along with the market to what I believe is a very favorable entry point as shares closed at $3.86.

Let's first note that that an 8-K filing from March 30 tells us that Robert Roskamp, the Director of the Roskamp Institute bought $1,000,000 of “additional” stock and warrants at $4.00.* Certainly, if the director of the Institute, who must know more about how their research is going bought more stock it's pretty clear to me that this would be a good place to add to positions or institute a new position if you weren't already a shareholder.

Importantly that “buy” by Mr. Roskamp adds to last year’s $1,000,000 purchase of 769,000 shares and the rights / warrants to buy another million shares at $1.30.

To further hammer home the belief that this is a good entry point is that the successes of the Roskamp Institute's research is light-years ahead of where it was last March. Last month the Roskamp Institute posted an Update on 'inflammaging' research at the Roskamp Institute. The data demonstrates the anti-inflammatory properties of (RCP-006) in comparison to NSAIDs in whole human blood.

The graph demonstrates vividly how (RCP-006) is more than four (4) times more effective than either Celebrex or Voltarol in reducing inflammation. Both Celebrex and Voltarol are powerful non-steroidal anti-inflammatory drugs, have helped millions of people and have sold in the billions of dollars. Unfortunately recent news of major side effects has affected their sales to large degree. Both are drugs that require prescriptions from a physician. Also vital in this analysis is that previous research from a few months ago demonstrated the dramatic effect of anatabine (RCP-006) versus Lipitor, well known to have advanced anti-inflammatory properties. (RCP-006) was shown to be more than three (3) times more effective than Lipitor in reducing inflammation. Lipitor sales in 2010 were $10.7 billion.

Just grasp the market for an over-the-counter item, (a nutritional supplement) that could have these astonishing successes; it's of mind-boggling proportions.

In one of my reports last year on Star Scientific (shares were $1.67 at the time) I spoke of how CigRx™ was so successful in quelling my urge to smoke cigars; and it continues to do just that. Now, since I was "sampled" with Star Scientific’s product (RCP-006) Anatabloc™ (that’s used in the studies at Roskamp, Johns Hopkins, and in the Flint Study) I thought I would give you an update on my personal experience with the compound.



I've been taking the product for about two months now and have increased my dosage to about 10 of the tabs a day. I began by taking about six a day. My experience is that while I've yet to compare with previous blood tests to see its effect on a long-standing hypothyroid condition yet and that I will do next month, I can tell you that I have had dramatic improvement in dealing with my enlarged prostate [BPH] condition. My physician tells me that my prostate is healthy, soft, noncancerous, but quite enlarged. The condition “BPH” causes a number of bothersome symptoms that I'll let you link to via the hyperlink. Anyway, the short version is I only have to get up a couple of times a night and the ease of flow of urine is hugely improved. It's remarkable.

My wife also takes the Anatabloc ™ for the rheumatoid arthritis centered in her hands and she has experienced less swelling, less pain and increased mobility. We are both extremely pleased with the results to put it mildly. Understandably, these are anecdotal stories about the compound success, but when they are personal it takes on another dimension. In both our cases this product we believe has improved our life, and I might add that we both feel a bit more spry.

Because I've been writing about Star Scientific for about a year now I am pretty accessible to those people, their loved ones and investors who have taken Star’s products. From these people I've heard numerous anecdotal stories of the extraordinary successes of the (RCP-006) compound. They include major improvements in rheumatoid arthritis, carpal tunnel syndrome, dementia, irritable bowel syndrome, Crohn's disease, thyroid conditions and other assorted conditions related to aging. Obviously, something is going on here. And when you access and read that recent Roskamp research about (RCP-006) Anatabloc ™ Update on 'inflammaging' research at the Roskamp Institute it becomes pretty clear that there will soon be a very effective new way to deal with some very nasty medical conditions on the market.

Star Scientific’s product, (RCP-006) targets low grade inflammations that is present in a number of coronary and vascular diseases, and in auto-immune diseases such as thyroid disease, diabetes and arthritis and numerous other conditions.

The Roskamp Institute funded by the National Institutes of Health and private donations, is conducting research using (RCP-006) on Alzheimer’s disease, gastroenterology, rheumatology, cancer, auto-immune diseases (lupus), and cardio-atherogenesis (the process of atheromatous plaque development in arteries), among other conditions.

I just received a link to and article in the Sarasota Herald-Tribune that I hadn't seen before: http://www.heraldtribune.com/article/20110521/ARTICLE/110529811?p=all&tc=pgall&tc=ar him

Also item of note: the (RCP-006) product CigRx™, which reduces the urge to smoke, has over 54,000 “friends” on Facebook, up from about 5,000 a couple of months ago. http://www.facebook.com/CigRx

Another notable metric mentioned at the Roskamp meeting is that about 100,000 people have now taken (RCP-006) compounds.

Check out the web-site that describes CigRx™ and how to purchase the lozenges. The site has an exceptional and professional look with testimonials and video links?It's a powerful sell. The website, www.cigrx.com

Disclaimer: I'm an investor in Star Scientific Inc. (CIGX) shares and have no other affiliation with the company than as a shareholder. I have purchased shares of Star Scientific in the open market.

To view the (CIGX) website: http://www.starscientific.com

* On March 30, 2011, Star Scientific, Inc. (the "Company") entered into a Securities Purchase and Registration Rights Agreement (the "March 30 Agreement") with an accredited investor (the "March 30 Investor") to sell 254,452 shares (the "March 30 Shares") of the Company's common stock, par value $0.0001 per share ("Common Stock"), at $3.93 per share and warrants to purchase an aggregate of 254,452 shares of Common Stock at an exercise price of $4.00 per share (the "Warrants") (collectively, the "March 30 Offering"). The March 30 Offering resulted in gross proceeds to the Company of $1,000,000. The Warrants are first exercisable on September 30, 2011 and expire on September 30, 2016.

THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, Robert G. Roskamp (the “Holder”), is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after September 30, 2011 (the “Initial Exercise Date”) and on or prior to the close of business on September 30, 2016 (the “Termination Date”) but not thereafter (the “Exercise Period”), to subscribe for and purchase from Star Scientific, Inc.,

"Two cases of a new strain of swine-flu related infection have been reported in young children, according to the Centers for Disease Control and Prevention Friday."

http://www.msnbc.msn.com/id/44373159/ns/health-cold_and_flu/#.TmFSQGodxrA

"Seeking Alpha" may be a consideration as a vehicle to spread the SRSR story. Their requirements for a person submitting an article do not seem overly stringent. However, they publish approximately 250 articles per day selected from over 1000 daily submissions.

http://seekingalpha.com/

Sleeper 43-101 is planned to be released early Sept. 2011 (2-3 weeks).

Early estimates are as high as $70mm recoverable gold in the tailings

lousy engineer,

Thanks for posting the links. Please consider "sticky noting" these.

As new potential investors come to this board they may have a lot of questions. Pointing them to informative "sticky notes" would be most helpful.

seeker_of_value,

I am enjoying your observations and questions and encourage you to continue.

As with any start up, Nanoviricides Inc. needs to attract and retain new investors. Do not let anyone alienate you. Do your d/d and draw your own conclusions.

Eva Harris is working with the Dengue viricide. Things have been quiet for awhile. NNVC seems to have a history of repeatedly raising the bar by tweaking the "cide" in an effort to improve efficacy.

My gut feel is that the Dengue "cide" is near maximum efficacy and stellar results will be announced in the upcoming months.

Forzanano,

Last evening I found time to read your post regarding the FDA.

I found it informative.

Thank you.

Echo,

My I offer a slight disagreement with you about NNVC data being seen for the first time by anyone outside NNVC?

I am in full agreement with you that this may be the first time that all NNVC data is being seen by an outside party.

Would it be safe to assume that Biologics Consulting signed a confidentiality agreement prior to a formal contract with NNVC?

This would have given Biologics the opportunity to preview NNVC's data and write a proposal that outlines a strategy, a project plan overview, an analysis of a successful outcome, and a price.

I don't recall if the financial terms of the agreement between Biologics and NNVC were disclosed. But I'm confident that the amount of money involved would require a tightly formal agreement.

Is NNVC legally or ethically bound to publicly communicate that a pre-IND meeting is scheduled or has taken place?

I'm wondering if it could be strategically wise for NNVC to operate in a 'cone of silence' until FDA grants (or denies) IND status.

Would the pre-IND stage present an opportunity for those whose who feel their market share could be threatened to exert influence on the FDA?

Of particular concern is Flu-cide. The OTC market for cold & flu remedies is staggering and involves some very big and influential players.

As much as I would like to hear of a scheduled pre-IND meeting I could tolerate not knowing if it were in NNVC's best interest.

My questions are probably more about my 3rd cup of coffee on a Saturday morning than anything else.

keltoi,

"I think there are enough posters who value my opinions ....".

Count me as one who values your opinion and also the opinions numerous other posters. This includes those with whom I don't always agree with but continue to respect.

I regard the NNVC IHUB board as a reliable source of information and often serves as a jumping off point for my own due diligence.

Of course there are always a few individuals who I regard as low "value add" as they appear to have troubling incitement agendas.

The story of my experience was anecdotal. I worked for Novartis at the time but was not involved in the relationship with WHO.

Should NNVC find themselves in a WHO bidding situation I'm sure they'll do the right thing.

NNVC hiring outside consultants for their pre-IND and IND efforts sends a positive message that they aren't above seeking outside expertise.

Echo,

I don't have the knowledge to address HIV treatment.

I could have done a better job of presenting my point.

My story around Novartis was based on the WHO taking bids from a few pharmas having comparable anti-malarial drugs. Novartis made International news with their offer of $1.50 per day. If I remember correctly the next lowest bid was $7.50.

Obviously not an apples-to-apples comparison with NNVC "cides". My point is that should NNVC decide to be altruistic and the WHO is interested there would be an efficient distribution channel in place via WHO.

The WHO (World Health Organization) takes "bids" from drug manufacturers. This is often a charitable donation on the pharma company's part.

At one point Novartis got the "bid" for their anti-malarial drug at $1.50 per dose. This was far below actual cost but through a cooperative effort between the manufacturer and contributions from WHO members to cover the $1.50 dosage cost more people could be treated.

New treatments from small companies that aren't cash heavy could possibly use this model treat patients in 3rd world countries at cost or a skinny gross profit margin.

NNVC's "cides" seems like a perfect fit for a program of this type.

As a NNVC shareholder I would fully support this.

As a new investor in SRSR I found the "sticky note" posts of great help. This company fascinates me and over time I hope to acquire additional shares.

I have one question that I've not been able to independently answer. The charts indicate a significant spike in mid 2009. I've not been able to sleuth out what drove this.

Also, there are numerous smaller spikes followed by a draw down. Were these spike driven by hard news or the hope of news?

I'm not asking for a prediction around the most recent jump. I am asking for observations on the historical spikes.

Funds are limited so, more than ever, I am driven by getting the most bang for my buck.

I feel that a part of a PR's function is to attract and retain new investors.

I've walked into a restaurant after being lured by a good smell of food cooking. I go inside to learn more and possibly buy.

I think that PR's should be functional on two levels. Attracting new investors via a compelling introductory paragraph(s) and providing detailed information to both new and knowledgeable investors.

It is a given that the burden of due diligence lies with the prospective investor.

Keltoi,

SPOT ON!

Thank you for an excellent job of driving home my point. My thoughts are that Seymour is a brilliant scientist who largely talks to other scientists on a level this "caveman" doesn't always comprehend. What may seem elementary to Seymour can sound like a foreign language to myself and others.

Also, thank you for contacting Seymour and voicing your and others' concerns. The fact that he was receptive to your comments reflects positively on him.

My earlier comment seems to have resonated with several of you in various ways.

Dare I go so far as to say I may have caused a minor kerfuffle?

Please allow me to clarify the intent of my original message.

My message was intended to be constructive rather than critical.

Dr. Feelgood received an email from Seymour which clarified a paragraph that I admit to not having initially grasped. Seymour also said he was open to suggestion on how to improve PR's.

Dr. Feelgood has a command of the written word and a strong awareness of the science around NNVC. It seemed logical to me to inquire whether, if it were legal/ethical, Dr. Feelgood would be willing to review PRs from a communication standpoint prior to release.

Dr Feelgood,

Do you know who writes NNVC's PRs? If they are written "in house" would you consider offering your editing/review services to NNVC?

This is not intended to be critical of Seymour and Diwan. I'm thinking that you could offer a "forest vs tree" perspective.

Hello everyone. I own some SRSR and have been quietly following your discussions.

This "Jim" guy seems to be a legend. Could one of you provide his username so I can try find some of his old posts? They sound like worthwhile reading.

Any assistance will be appreciated.

Small Pox comes to mind. As does Scarlet Fever. Rubella?

No intention of offending but not sure I understand your question.

Self characterization would describe me as a quiet but significant investor in NNVC.

I like this board because there are several knowledgeable people posting here.

The old adage, "Two ears one mouth. Use accordingly" is my personal stance. But that's just me.

<Like>

Yes, they are expensive and appear to be well worth it.

I think this was a brilliant move on Seymour and Diwan's part.

Here's their rates: http://www.bcg-usa.com/services/rates.php

nanopatent,

I wasn't challenging your having posted the article. Like you, I was wondering if it could be relevant.

I appreciate any relevant article postings. Usually someone comes along and explains the parts I don't grasp.

I think I understand the article's message but I am not able to determine if this is a threat to NNVC's success.

Is the article stating nanoparticles in general are toxic, some are and some aren't, or we don't know?

It's my understanding the NNVC's product is expelled from the body. Does this article imply that if the nanoviricides enter a cell it will not be expelled?

My questions may be simple but they are sincere.

Keltoi,

I believe you are spot on.

Yes, NNVC has the potential to dramatically impact OTC (over-the-counter) remedies. It's a big dollar industry.

Teedlum

I agree with your assessment. To properly sell a steak the buyer needs to 'hear' the sizzle.

One can radiate enthusiasm without appearing to be a carnival barker.

I admire Seymour and it is my sincere & constructive suggestion that he get some outside coaching on presenting the NNVC story.

You can save your sarcasm for someone who appreciates it.

I stated a fact about Yahoo board posts.

I hypothesized the they were both shorters and amateurs.

I acknowledged Dr Feelgood's efforts to keep the record straight.

You assumed that I was justifying the current price movement.

There's some clown(s) on the Yahoo message board repeatedly posting false info. SEC Wells Notice, insider dumping (Diwan) and the usual "NNVC is a scam" mantra.

Obviously shorters. Obviously amateurs.

Doc Feelgood soundly bitch slapped them. Good work doc!